Skip to main content
. Author manuscript; available in PMC: 2022 Aug 13.
Published in final edited form as: ACS Infect Dis. 2021 Jun 11;7(8):2413–2424. doi: 10.1021/acsinfecdis.1c00158

Table 1.

Antibacterial Activities Against Wild-Type E. coli and ESKAPE Pathogens (MIC, μg/mL)a

Species MRSA E. coli K. pneu. Enterob. A. baum. P. aerug. b
Strain AG038 AG001 AG215 AG290 AG225 AG220
Propylamycin 1 1–2 1 0.25–0.5 0.5 1–2 8–16
Paromomycin 2 2 2–4 1 2 2–4 >128
Lividomycin B 3 4 4–8 2 2 4 4
8 2 2 1 1 2 4
9 1–2 2–4 1 4 4 4
10 2 2–4 2 8 8 16
11 1 1 1 1 2 8
12 2 4 2–4 2–4 2–4 128
13 2 2–4 2 2 2 4
14 2 1–2 1 1 2 4
15 4 4 2 2 32 >64
Gentamicin 1–2 0.5–1 0.25 0.25 0.5–1 1
Plazomicin 2 1 0.5 0.5 2 2–4
a)

All values were determined in duplicate using twofold dilution series.

b)

P. aeruginosa carries a chromosomal APH(3’) gene, which principally affects the 3’-hydroxy group.